Close menu




November 7th, 2024 | 07:15 CET

TUI, Evotec, BioNxt Solutions: Short squeeze potential, Price drops, and Momentum

  • Biotechnology
  • Biotech
  • Travel
Photo credits: BASF SE

BioNxt Solutions' stock has gained 50% since the end of August. The chances are good that the momentum will continue for the biotech company. The stock would need to more than double to reach its January level. The industry environment is favorable, the news flow is positive, and takeover speculation exists. Takeover speculation is perhaps the only positive factor for Evotec's share at the moment. The operational development is certainly not. Yesterday, the Company reported a significant drop in earnings. Is there any improvement in sight? Operationally, TUI has been doing well for quite some time. With a jump in the share price, the stock is now setting its sights on the resistance at EUR 8. Could there even be a short squeeze? Analysts may also shift to the bull camp.

time to read: 4 minutes | Author: Fabian Lorenz
ISIN: TUI AG NA O.N. | DE000TUAG505 , EVOTEC SE INH O.N. | DE0005664809 , Bionxt Solutions Inc. | CA0909741062

Table of contents:


    Sébastien Plouffe, CEO, Founder and Director, Defence Therapeutics Inc.
    "[...] Defence will continue to develop its Antibody Drug Conjugates "ADC" and its radiopharmaceuticals programs, which are currently two of the hottest products in demand in the pharma industries where significant consolidations and take-overs occurred. [...]" Sébastien Plouffe, CEO, Founder and Director, Defence Therapeutics Inc.

    Full interview

     

    BioNxt Solutions: Another 100% upside potential?

    BioNxt Solutions' shares have gained 50% since the end of August. Will the momentum of the biotech stock continue, and is it still a buy? The chances of the rally continuing are good. Not only has sentiment in the sector improved significantly in recent months – see the jump in BioNTech's share price – but the share price increase is also based on numerous positive operational announcements by the Company. At a price of EUR 0.16, the market capitalization is around CAD 30 million. At the beginning of 2024, the price was EUR 0.50. Since then, however, the Company has made significant progress, and the positive news flow is likely to continue in the coming months.

    The leading drug development program in BioNxt's portfolio for autoimmune neurodegenerative diseases is a proprietary sublingual alternative for the already approved drug cladribine for the treatment of multiple sclerosis (MS). Sublingual means that the patient only has to place the medication under the tongue. It is designed to offer patients with swallowing difficulties (dysphagia) – a common condition in MS patients – a significant advantage over the tablet form. Cladribine is currently available in tablet form in more than 75 countries and, according to the manufacturer Merck KGaA, had annual sales of over USD 1 billion in 2023. Thanks to BioNxt, sales could increase and potentially generate several million euros in revenue for BioNxt.

    BioNxt also has a foot in the door in the currently very hot and takeover-driven cancer therapies sector. For example, the European Patent Office (EPO) has approved the patent application for the sublingual administration of cancer drugs for the treatment of neurodegenerative autoimmune diseases. Approval should be granted soon, and further applications are planned for the US, China, and Japan. BioNxt also wants to expand its patent portfolio in the field of cancer to include orally dispersible films. These contain substances to protect against cancer in neurodegenerative diseases.

    BioNxt has a broad portfolio, which fuels ongoing speculation about potential acquisitions. Perhaps the German company Merck?

    Evotec: Quarterly figures and share price in the red

    As we have speculated before, the recently released figures from Evotec have not brought joy to shareholders. The share price plunged by double-digits, ending the price rally that started in early October. The biotech company is in the middle of a restructuring, and the new management board is working to free itself from all legacy issues before moving forward.

    Evotec CEO Dr. Christian Wojczewski commented: "We continue to successfully implement our 'priority reset', and have made significant progress on key initiatives. New and expanded partnerships clearly demonstrate Evotec's continued leadership in R&D and precision medicine. Building on this exceptionally strong foundation, we are now laying the groundwork for an accelerated transformation program that will pave the way for long-term profitable growth. While the challenging market environment has affected short-term results, we are making great strides in reviewing strategic priorities and look forward to reporting on this in early 2025."

    In the first nine months of 2024, Evotec generated revenues of EUR 575.7 million, 1% less than the previous year. There was a sharp decline in earnings. Reorganization costs of EUR 62 million were reported. Adjusted Group EBITDA fell from EUR 50.2 million to EUR -6.0 million (9M 2023: EUR 50.2 million), and the operating result dropped significantly from EUR -36 million to EUR -149.3 million.

    TUI: Short Squeeze possible?

    Those who speculated that severe weather in Spain - an important travel destination - would negatively affect TUI stock were disappointed. On the contrary, the stock has been strong, surging toward the EUR 8 mark. This is a level the tourism group's share has not seen in over a year. If the EUR 8 mark is surpassed, the next major hurdle would likely be between EUR 10 and 11.

    There are no operational reports as a reason for the recent price jump, but operationally, TUI has been doing well all year. Booking numbers are rising, profits are rising, and debt is expected to be reduced. In addition to analysts, short sellers have also been skeptical about the recovery so far. Accordingly, the short rate for TUI was previously high. But slowly, the shorties seem to be running out of steam. According to shortsell.eu, the ratio has now fallen to 11.3%. This is still relatively high, but the trend is pointing downwards. D.E. Shaw & Co, Gladstone Capital Management, LMR Partners LLP, Two Sigma Investments Marshall Wace LLP and Qube Research & Technologies Limited are the short sellers with the largest positions in TUI. According to the Federal Gazette, the last two addresses have started to reduce their positions. If this trend continues, the share price should head towards EUR 10. Especially if one or the other analyst also switches to the camp of the bulls – which is not unlikely given the operating performance.


    Betting on a strong short squeeze at TUI would probably be an exaggeration, but the tourism group's operations have been running smoothly for some time, and a breakout above EUR 8 would also make the chart picture interesting. The BioNxt share has a lot of momentum. If the news flow remains positive, at least the price level from the beginning of 2024 should be achievable. Evotec is certainly exciting at its current price level, but it will likely take time to realign the Company – if a takeover does not happen first.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.


    Der Autor

    Fabian Lorenz

    For more than twenty years, the Cologne native has been intensively involved with the stock market, both professionally and privately. He is particularly passionate about national and international small and micro caps.

    About the author



    Related comments:

    Commented by André Will-Laudien on December 11th, 2024 | 07:15 CET

    DAX 25,000 and gold at 3,500 next year? Position now with Lufthansa, TUI, Desert Gold, and Barrick Gold

    • Mining
    • Gold
    • Travel

    After an extensive stock rally in 2024, many investors are wondering what the New Year 2025 will bring in terms of investments. Hopes are resting, on the one hand, on the upcoming conservative government changes in the US and Germany. There is great confidence in a new supply-side industrial policy flanked by further interest rate reduction measures. Deregulation of bureaucracy and tax relief could usher in a new era of corporate profitability, especially in Germany. This might eventually lead to the return of foreign investments and job creation, replacing the red-green visions of a carbon-neutral 28-hour workweek with full pay. We provide some insights on where and how profits might flow again.

    Read

    Commented by Stefan Feulner on December 10th, 2024 | 07:30 CET

    Novo Nordisk, BioNxt Solutions, Bayer – The market continues to boom

    • Biotechnology
    • Biotech
    • Pharma

    The weight-loss drug market was one of the fastest-growing sectors in the past year and shows no signs of slowing down in 2025. Companies like Novo Nordisk have seen their valuations multiply in recent years, significantly boosting their market capitalization. At the same time, smaller life sciences companies in the second tier, such as those with breakthrough technologies, offer interesting entry opportunities.

    Read

    Commented by Fabian Lorenz on December 10th, 2024 | 07:15 CET

    HIGHFLYER stocks with upside potential: Renk, TUI, Almonty Industries

    • Mining
    • Tungsten
    • Defense
    • Travel

    The current year has seen the beginning of a revaluation of Almonty Industries. The tungsten producer's stock has already gained more than 50%. If analysts have their way, it could gain another 250%. According to analysts, there could still be over 250% upside potential, as the Company is on the verge of a revenue and profit surge with the opening of a mega-mine. The TUI share has finally jumped above the EUR 8 mark. Driven by statements about a strong summer season in 2025, there is room for further growth. At its IPO, Renk was sold as a high-flyer in the defense sector. While the Company has yet to live up to these high expectations, analysts see over 50% price potential.

    Read